Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 14/20 | 0.48 |
| ▸ | CA2 | P00918 | 14/20 | 0.48 |
| ▸ | CA4 | P22748 | 7/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13273544 | 0.94 | CA1 (0.46) | TERTCA1CA2CA4CA12 | |
| SCHEMBL10001927 | 0.86 | TERT (0.40) | TERTCA1CA2CA4CA12 | |
| SCHEMBL23130692 | 0.85 | TERT (0.43) | TERTCA1CA12CA9HPGD | |
| SCHEMBL15161172 | 0.85 | CA1 (0.48) | TERTCA1CA2CA4CA12 | |
| SCHEMBL10035654 | 0.85 | TERT (0.55) | TERTLMNAALDH1A1 | |
| SCHEMBL17365333 | 0.84 | CA1 (0.52) | CA1CA2CA4CA12CA9 | |
| SCHEMBL10035653 | 0.84 | TERT (0.54) | TERTLMNA | |
| SCHEMBL23153405 | 0.81 | POLB (0.42) | TERTHPGDKDM4EALDH1A1GLA | |
| SCHEMBL19234764 | 0.80 | TERT (0.43) | TERTCA1CA2CA4CA12 | |
| SCHEMBL15159293 | 0.80 | CA1 (0.45) | TERTCA1CA2CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297690-B2 | Fluorescent lanthadine complex | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-11-20 | — | — | US | disclosed |
| US-7297690-B2 | Fluorescent lanthadine complex | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-11-20 | — | — | US | disclosed |
| US-20070026407-A1 | Novel fine fluorescent particle | WASEDA UNIVERSITY (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070026407-A1 | Novel fine fluorescent particle | WASEDA UNIVERSITY (JP) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070026407-A1 | Novel fine fluorescent particle | SPECC1L, RAB5IF, NSFL1C | TERT 4109/4885CA1 577/4885CA2 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.